INS018_055

Kakao Healthcare Corp. is launching its AI-powered continuous glucose monitoring app PASTA in Japan through a new subsidiary, marking a significant step in the company's global expansion strategy.

Pliant Therapeutics has temporarily suspended enrollment and dosing in its Phase IIb/III BEACON-IPF trial of Bexotegrast following recommendations from the independent Data Safety Monitoring Board.

Isomorphic Labs, a Google DeepMind spinoff, anticipates initiating clinical trials for AI-designed drugs by the end of 2025, potentially revolutionizing drug discovery.

Boehringer Ingelheim's nerandomilast met its primary endpoint in the Phase III FIBRONEER-ILD trial, improving lung function in patients with progressive pulmonary fibrosis.

Insilico Medicine's ISM5411, an AI-designed gut-restricted PHD inhibitor, demonstrates favorable safety and tolerability in Phase I trials for inflammatory bowel disease (IBD).